Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Human Factor XIII Concentrate in Congenital Factor XIII Deficiency
NCT00883090Phase 2Completed
- Sponsor
- CSL Limited
- Start
- May 2009
- Primary completion
- Apr 2010
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of Factor XIII (human) in congenital factor XIII deficiency, sponsored by CSL Limited. Primary endpoints: Peak FXIII Concentration at Steady State at 12 weeks, Trough FXIII Concentration at Steady State at 12 weeks and 7 more. Started May 2009; status: completed.
02
Drugs
Factor XIII (human)
03
Conditions
congenital factor XIII deficiency
Beyond the preview
Go deeper on NCT00883090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00883090.